Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) - MK-3475-02B - Merck Sharp & Dohme LLCSee more
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) - PRISM-MEL-301 - Immunocore LtdSee more
A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) - V940-007 - Merck Sharp & Dohme LLCSee more
Breast Cancer
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) - MK-2870-012 - Merck Sharp & Dohme LLCSee more
Cardiac arrhythmia
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation - LIBREXIA-AF - Janssen Research & Development, LLCSee more
